Anti-CD200R1 Antibodies for Complete Immune Checkpoint Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting CD200R1, such as Samalizumab, are limited in their ability to effectively block the immune regulatory effects mediated by CD200R1, leading to incomplete tumor suppression and reduced patient survival in cancers like chronic lymphocytic leukemia and multiple myeloma.
Innovation Solution
Development of antibodies with high affinity for human CD200R1 that can fully block or inhibit immune regulatory effects, including specific hypervariable regions and binding properties to achieve complete immune activation and tumor suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Samalizumab is used to target CD200R1, then immune regulatory effects are blocked to some extent, but the blocking is incomplete leading to reduced tumor suppression
Solution Approach 1:
The patent applies parameter changes by developing antibodies with optimized binding affinity and specificity parameters. The anti-CD200R1 antibodies are engineered to have higher binding affinity and more complete blocking capability compared to Samalizumab, directly addressing the incomplete blocking issue while maintaining tumor suppression efficacy.
2Reliability
If antibodies with high affinity for CD200R1 are developed, then complete immune activation and tumor suppression are achieved, but the complexity of identifying specific hypervariable regions increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody structure into distinct hypervariable regions (HVRs) and framework regions. By identifying and optimizing specific HVRs responsible for high-affinity binding to CD200R1, the patent simplifies the design process while achieving complete immune activation, rather than treating the entire antibody as a single complex unit.
Solution Approach 2:
The patent applies local quality by focusing optimization efforts on specific hypervariable regions rather than the entire antibody structure. The patent identifies particular HVRs that confer high binding affinity and complete blocking capability, allowing localized optimization that reduces overall complexity while maintaining high reliability of immune activation.
3Productivity
If current CD200R1 therapies are used, then some tumor burden reduction is achieved, but patient survival is reduced due to incomplete blocking
Solution Approach 1:
The patent applies preliminary anti-action by developing antibodies that preemptively achieve complete blocking of CD200R1 before tumor progression can occur. The high-affinity anti-CD200R1 antibodies are designed to fully inhibit immune regulatory effects from the outset, preventing the incomplete blocking that leads to reduced patient survival, rather than merely reducing tumor burden partially.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies enhance immune activation, increase cytokine production, and block CD200R1 signaling, providing therapeutic benefits in various cancers with minimal off-target effects.
Implementation Method 1
anti-CD200R1 antibodies and antigen-binding fragments that specifically bind human CD200R1 with high affinity
Implementation Method 2
The antibodies are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by CD200R1
Data Source
AI summary
The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.